RNatives is thrilled to announce that the company has successfully raised $1,400,000 in new funding, marking a significant milestone in our journey to revolutionize gene modulation therapeutics. As a pioneering platform company, RNatives harnesses the novel biology of nuclear microRNAs to modulate gene expression of desired target genes, setting a new course for targeted therapies. Our proprietary platform technology, built on years of rigorous academic research and validated in studies published by Turunen et al., is designed to empower the body's own mechanisms to address serious health conditions. The current funding will primarily focus on the upregulation of the endogenous VEGFA gene, a crucial step in treating diseases such as myocardial ischemia and peripheral artery disease. By increasing the cell's natural production of VEGFA through small RNA modulation, we aim to trigger neovascularization in affected tissues, paving the way for improved blood flow and recovery in patients suffering from these debilitating conditions.
This round of funding not only underscores the strong confidence that investors have in the transformative potential of our technology, but also provides the resources needed to advance our research and clinical development efforts. With these funds, RNatives will expedite the scaling up of our proprietary platform and further explore the therapeutic applications of nuclear microRNA biology in a broader range of diseases. We believe that by working at the intersection of innovative biology and bold new technology, we can offer hope and tangible health benefits to patients worldwide. As we celebrate this important achievement, we remain committed to pushing the boundaries of gene therapy research and delivering impactful solutions that enhance quality of life.
